ImmuCell Full Year 2024 Earnings: US$0.26 loss per share (vs US$0.74 loss in FY 2023)

ImmuCell (NASDAQ:ICCC) Full Year 2024 Results

Key Financial Results

• Revenue: US$26.5m (up 52% from FY 2023).
• Net loss: US$2.16m (loss narrowed by 63% from FY 2023).
• US$0.26 loss per share (improved from US$0.74 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Scours segment contributing a total revenue of US$26.3m (99% of total revenue). Notably, cost of sales worth US$18.1m amounted to 68% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Research & Development (R&D) costs, amounting to US$3.90m (37% of total expenses). Explore how ICCC's revenue and expenses shape its earnings.

ImmuCell shares are up 13% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 3 warning signs for ImmuCell (of which 1 is significant!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.